about
Testosterone and vascular function in agingO-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathwayExtracellular signal-regulated kinase 1/2 activation, via downregulation of mitogen-activated protein kinase phosphatase 1, mediates sex differences in desoxycorticosterone acetate-salt hypertension vascular reactivity.O-GlcNAcylation contributes to augmented vascular reactivity induced by endothelin 1.Cigarette smoking and erectile dysfunction: focus on NO bioavailability and ROS generation.Adenosine actions are preserved in corpus cavernosum from obese and type II diabetic db/db mouse.Erectile dysfunction in young non-obese type II diabetic Goto-Kakizaki rats is associated with decreased eNOS phosphorylation at Ser1177Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats.Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1Diabetes impairs the vascular effects of aldosterone mediated by G protein-coupled estrogen receptor activationDifferential modulation of nitric oxide synthases in aging: therapeutic opportunities.Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?TNF-alpha infusion impairs corpora cavernosa reactivityEmerging role for TNF-α in erectile dysfunction.There is a link between erectile dysfunction and heart failure: it could be inflammation.TNF-alpha knockout mice have increased corpora cavernosa relaxation.Toll-like receptor 9 plays a key role in the autonomic cardiac and baroreflex control of arterial pressure.Hypertension: a new treatment for an old disease? Targeting the immune systemDetermination of Adenosine Effects and Adenosine Receptors in Murine Corpus CavernosumTargets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
P50
Q28383213-7D9A6ABF-1A39-46A7-92CC-4D98D2EE7F9BQ28571140-D55C4CB6-599F-4EC6-9F71-0E1E18E6AFDAQ33572366-F8B98E2A-F4D4-4008-B5A2-1AACD9880599Q33599905-84D3ED45-3F1F-4171-BC48-62FBFE514799Q34412164-B7BDDE8A-2569-4DBA-AFB5-045F6C7DBA13Q34469704-C93E0486-4F51-408C-8200-B365989503B7Q34498189-C5384AEC-8A40-4E3F-8421-C7F5E166AD9DQ34705086-A371BDB2-B526-4110-9B17-56211A04FD13Q34780141-DEE2BDC5-38AF-4A4A-A1AB-F362FB8B8AC2Q35135440-C41131F1-A516-4708-8E2C-78FADB8E306AQ36056243-7AE78FC6-7A7E-45C9-B371-5108F1B26A93Q37082781-8AABE761-F9E9-4657-A290-978FBADB5C6CQ37240796-CAE33119-0DCA-44EF-AE56-6EA58FD42577Q37719686-E620C5BB-58FB-49FC-93F2-ED4621FEAEAFQ38429060-1B3F85E4-BEA2-478B-AB63-C49646B0F075Q39736808-0C7CE77C-1988-4B2D-97B3-1FF668C19D48Q47746395-6C3075BE-7DDB-40C8-95E8-C9AAA77DA670Q57772657-30829395-6B06-4101-828B-E25A5B94BB15Q57772675-95118F30-D3F5-4339-B843-7D05015B41C7Q57772676-5CEBE42C-5649-4D8A-AC90-FBB8601D3D8D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fernando Silva Carneiro
@ast
Fernando Silva Carneiro
@en
Fernando Silva Carneiro
@es
Fernando Silva Carneiro
@nl
type
label
Fernando Silva Carneiro
@ast
Fernando Silva Carneiro
@en
Fernando Silva Carneiro
@es
Fernando Silva Carneiro
@nl
prefLabel
Fernando Silva Carneiro
@ast
Fernando Silva Carneiro
@en
Fernando Silva Carneiro
@es
Fernando Silva Carneiro
@nl
P106
P1153
56265891200
P21
P31
P496
0000-0003-4519-6513